Dova’s Doptelet Gets First-To-Market Edge In Thrombocytopenia, Ahead Of Shionogi
Executive Summary
Dova CEO Alex Sapir very confident of oral thrombopoietin receptor antagonist’s chances of taking market share from current standard of care, platelet transfusions, citing safety and convenience advantages.
You may also be interested in...
Deal Watch: Pfizer Offloads Troubled ADHD Products To Manufacturer Tris
Tris acquires Pfizer subsidiary Nextwave, which developed pair of ADHD drugs using Tris delivery technology. Lilly gets oral CGRP candidate from Chugai, while Dova signs US co-promotion partner for Doptelet.
Keeping Track: Shionogi, Fresenius Kabi Join July Approval Parade; Busy August Expected
The latest drug development news and highlights from our US FDA Performance Tracker.
14 Approvals To Look Out For In Q3
As many as 14 new products are up for US approval in the third quarter, research by Informa Pharma's Biomedtracker shows. Scrip takes a look at the candidates and their chances of reaching the market.